Vmbook Online ordering

Biotechnology

I am not a stock trading expert, but I can provide you with some general information about the public biotechnology company, Precipio, Inc. (PP Hermes, or PPHM), which is traded on the OTCQB venture market in the USA.

Precipio is a company focused on improving patient outcomes, through the development of chemotherapy companion diagnostics and personalized cancer therapies. Their business model is based on providing specialized services to clinical labs, physicians, and healthcare systems while leveraging a unique platform that offers global access to the most advanced diagnostic techniques.

As of the time of writing, there is no current H1 (first-half) or Q2 (second-quarter) earnings report available for 2021. However, in Q1 2021, Precipio reported total revenue of $828,000, a 124% increase year over year. The net loss for Q1 2021 was $2.2 million or $(0.14) per share. It is essential to note that biotech companies, especially ones in the developmental stages, typically incur net losses as they invest in research and development.

To get the most up-to-date financial information on Precipio, including H1 and Q2 2021 results, you should visit their investor relations page on their website or review their Form 10-Q filings available on the Securities and Exchange Commission (SEC) EDGAR database.

It's important to conduct your due diligence and consult a financial advisor or investment professional before making any investment decisions based on this information. Keep in mind that investing in the stock market, especially in development-stage biotechnology companies, involves risks, and it's crucial to be informed about those risks before proceeding.